Level Four Advisory Services’s Fate Therapeutics FATE Stock Holding History

Level Four Advisory Services’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,517	Closed	-$208K	–	656
2021 Q3	$208K	Buy	3,517 +487	+16%	+$38.2K	0.02%	439
2021 Q2	$263K	Buy	+3,030	New	+$244K	0.02%	568

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Level Four Advisory Services's FATE Position: Q4 2021 in Review

Level Four Advisory Services sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 3,517 shares — an estimated $208K sold.

Level Four Advisory Services first reported a position in FATE in Q2 2021 and held it in 2 quarters. The position peaked at $263K in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

Level Four Advisory Services reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
Level Four Advisory Services sold 3,517 Fate Therapeutics shares in Q4 2021, an estimated $208K.
Level Four Advisory Services first reported a position in Fate Therapeutics in Q2 2021 and held it in 2 quarters.
Level Four Advisory Services's Fate Therapeutics position peaked at $263K in Q2 2021.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Level Four Advisory Services's 13F filing for Q4 2021, filed 11 Feb 2022.